NCT07042217Recruiting
Transcranial Direct Current Stimulation for Depression
A Randomized, Double-blind, Parallel-arm, Sham-controlled Trial of ElectraRx Mindfulness Transcranial Direct Current Treatment System (Elect-MDS) for Adults With Major Depressive Disorder
Source: ClinicalTrials.gov · Last updated 19 Oct 2026
Brief summary (registry, in English)
This study will test the efficacy of transcranial direct current stimulation (tDCS) combined with mindfulness, remotely-delivered using a telemedicine protocol in 25 adults with unipolar depression.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 11 Jun 2025
- Start date
- 1 Jul 2025
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- Soterix Medical
- Diseases
- Depression
- NCT number
- NCT07042217
What you commit to
- Study type: Interventional
- Planned participants: 25
- From 1 Jul 2025 to the primary completion date, 1 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Drug or alcohol abuse or dependence in the preceding 3 months
- Concurrent benzodiazepine medication
- Failure to respond to ECT treatment or rTMS treatment in this or any previous episode.
Other illness
- Failure to respond to at least 2 antidepressant medications
- Current DSM-V-TR psychotic disorder
- History of clinically defined neurological disorder or insult that may impact participation in this study as determined by study physician
- Implanted pump, neurostimulator, cardiac pacemaker or defibrillator
Other
- High suicide risk assessed during clinician screening at baseline interview.
- Metal in the cranium or skull defects
- Skin lesions on scalp at the proposed electrode sites
- Pregnancy
Who the study is looking for
- Clinically stable patients that meet criteria for diagnosis of MDD according to DSM-V-TR and confirmed with the Mini International Neuropsychiatric interview
- Currently experiencing a major depressive episode of at least 4 week's duration as part of a unipolar depression
- QIDS-SR score \>11 on all three days of screening week (Days 1,3, 7)
- Scored at least 17 (inclusive) on the HDRS-17 at trial entry
- Any antidepressant medication is stable ≥ 30 days prior to HDRS-17 screening
- Female patients are allowed if not pregnant and using a medically acceptable method of contraception, if of childbearing potential.
Age in the registry: 22 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Soterix Medical, Inc. Coordinator of this site? Confirm its status | Woodbridge | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.